FDA Clears Abbott’s Modified CGM For Automated Insulin Delivery Integration, Label Expansion
Executive Summary
Abbott announced today it plans to integrate its FDA-cleared modified CGMs with insulin pump makers, including Tandem and Insulet, likely later this year.
You may also be interested in...
Tandem’s CSO Speaks On Insulin Pump Development And Its Challenges
Insulin pumps have lagged behind continuous glucose monitors in terms of market penetration due to their cost and the complex regulatory framework that surrounds them. Elizabeth Gasser, chief strategy officer at Tandem Diabetes spoke to Medtech Insight about these challenges and how the company is taking a slightly different approach to pumps.
Minute Insight: Abbott Touts 14-Day FreeStyle Libre 3 Data
Shortly after the FDA approved Abbott's FreeStyle Libre 3 continuous glucose monitor system, the company announced new clinical data showing that it is the most accurate 14-day CGM system available.
LSI 2023: Intuitive Alums On Dawning Of Robotic Surgery To Digital OR Future
Robotic surgery pioneer and co-founder of Intuitive Surgical Frederic Moll joined Daniel Hawkins, Intuitive’s first non-technical hire, for a discussion on the evolution of surgical robotics and outlook for the future.